Developing Abuse-Deterrent

Medications to Reduce

the Potential for Harm

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders.

Prescription Stimulant Abuse is a Large and Growing Concern

5+ million

adolescents and adults misuse prescription stimulants annually1

From 2004 – 2011, emergency department visits due to non-medical use of stimulants2

Increased 4.7x

From 2010 – 2017, deaths associated with prescription stimulants3

Increased 5x

Sources: 1. SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2018; 2. Drug Abuse Warning Network, 2011; 3. Black, CPDD, 2020.

Our Technology is Designed to Resist Manipulation for Snorting and Provide Barriers to Injection

Our lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine  designed to deter attempts to crush and snort and provides barriers to injection.

Vallon News

Plugin JSON Content Importer Pro not running: Check Licence!
Plugin JSON Content Importer Pro not running: Check Licence!

Quick Links

Sign Up for Alerts